科研动态PubMed 摘要
首款mRNA癌症疫苗在III期试验中取得成功。
PubMed 白名单日捞 · 2026-10-26
完整摘要 · 中文译文
根据III期INTerpath-0001试验的结果，在黑色素瘤手术后，将基于mRNA的个体化新抗原疫苗intismeran autogene加用至PD-1抑制剂帕博利珠单抗治疗中，可将疾病复发或死亡风险降低42%。该数据在2026年10月23日至27日于西班牙马德里举行的ESMO大会上公布。
完整摘要 · 英文原文
Adding the mRNA-based individualized neoantigen vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death by 42%, according to the results of the phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.
English
First mRNA Cancer Vaccine Succeeds in Phase III Trial.